ScripPfizer’s recent exit from gene therapies was not an indictment of the safety and efficacy of gene and cellular therapies. Rather it was the latest example of the difficulties in commercializing these
ScripAnalysts have been queuing up to applaud MeiraGTx Holdings' innovative pact with artificial intelligence company Hologen which involves the establishment of a joint venture designed to get the UK/US
ScripMeiraGTx hopes to take a gene therapy candidate for Parkinson’s disease into Phase III based on positive efficacy and safety data from a small Phase II study that showed significant improvement on a d
ScripActuate Therapeutics, Inc. grossed $22.4m from its initial public offering of 2.8 million shares priced at $8 each in the 15th biopharmaceutical company IPO in the US in 2024. It was not the smallest